$MNKD ‘s newest FDA approved Furoscix ReadyFlow is an at-home treatment option designed to help adults with heart failure or chronic kidney disease address fluid overload earlier, before worsening symptoms may lead to emergency department visits, hospitalization, or readmission
1
124
Between rapid drug-delivery innovations and an expanding pipeline, $MNKD is set for growth in revenue and earnings. The gap between underlying fundamentals and market valuation is getting harder to ignore. Great takeaway 👇 by @Michaelluh on Stocktwits
1
120
$MNKD Wells Fargo raised PT to $14 from $11 on higher Furoscix & ‘201 probability of success, while keeping an Overweight rating on the shares. Informed by competitor PK/tissue exposure data, firm’s best estimate is that ‘201 is likely achieving better tissue exposure vs Ofev
1
106
$MNKD MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF investors.mannkindcorp.com/n…
127
Tanvi Patel retweeted
MannKind is excited to announce that the U.S. Food and Drug Administration (FDA) has approved a new, transformative delivery option for the treatment of fluid buildup due to heart failure or chronic kidney disease.
Designed for ease of use, this at-home administration option is delivered subcutaneously in seconds. Learn more in the Company Announcement here: bit.ly/4wgsmJ7
ISI: bit.ly/4wgsmJ7
Prescribing info: bit.ly/45gCm9r
Great news for kids. U.S. Food and Drug Administration (FDA) has approved Afrezza® (insulin human) Inhalation Powder for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetes #Needlefreeinsulin
#Diabetes #T1D #Type1Diabetes #T2D #WeAreNotWaiting
77
MannKind is excited to announce that the U.S. Food and Drug Administration (FDA) has approved the first needle-free treatment option for pediatric patients living with type 1 diabetes. Learn more in the Company Announcement here: bit.ly/4tYQgqV
Important Safety Information: bit.ly/4tYQgqV
Prescribing Information: bit.ly/4dBCEwL
#Press #FDA #Diabetes #T1D
Bodes well for $ABUS as it owns (w/h Genevant) the delivery technology used for mRNA vaccines. If $LLY buy abus, would $PFE make a counter offer as they have to pay for Abus’s intellectual property PFE used for COVID vaccines anyway cnbc.com/2026/05/27/eli-lill… cnbc.com/2026/05/27/eli-lill…
4
751
Tanvi Patel retweeted
𝐁𝐚𝐫𝐜𝐥𝐚𝐲𝐬 𝐌𝐢𝐚𝐦𝐢: In addition to being CEO of @MannKindCorp, Michael Castagna is a diabetic who uses his company's own product (Afrezza inhaled insulin). He demonstrated how it works. $MNKD



















